High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2010

Conditions
Multiple Myeloma
Interventions
DRUG

Cyclophosphamide

Cyclophosphamide as a white powder in 100 mg, 200 mg and 500 mg vials, to be dissolved in \~250 mL of saline or D5W and infused IV over 2 hours

DRUG

Etoposide

100 mg etoposide as 5 mL solution in clear ampules for injection.

DRUG

Melphalan

Melphalan as single-use glass vials of freeze-dried melphalan hydrochloride (equivalent to 50 mg of melphalan), to be reconstituted in 0.9% sodium chloride solution to not greater than 0.45 mg/mL, and administered within 1 hour of constitution.

DRUG

Carmustine

Carmustine as a powder for reconstitution in 100 mg vials, to be reconstituted with 3 mL sterile dehydrated ethanol and D5W. Carmustine should be dissolved in 500 mL of 5% dextrose in water (D5W) and infused IV over 2 hours.

DRUG

Filgrastim

Filgrastim in vials of 300 µg or 480 µg at a concentration of 300 µg/mL, to be given as a daily subcutaneous injection.

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT00349778 - High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma | Biotech Hunter | Biotech Hunter